Alcon to Acquire LumiThera and Its Pioneering Photobiomodulation Therapy Valeda for Dry AMD

Jul 08, 2025 16:31 CST Updated 16:31

LumiThera

Developer of LED and Laser Treatment Medical Devices for Acute and Chronic Eye Diseases

Alcon Announces Acquisition of Ophthalmic Phototherapy InnovatorLumiTheraAnd its PBM photobiomodulation therapy device for the treatment of early to mid-stage dry age-related macular degeneration (AMD) ---VALEDA。VALEDAIt is the only device proven to effectively improve baseline vision in patients with early to intermediate dry AMD.

Elcon's acquisition this time is mainly aimed at acquiringLumiTheraTheVALEDA, andLumiTheraOther BusinessAdaptDx, Nova/Diopsys will be divested, followingContinued byLumiTheraOperation of the shareholders' new company. This acquisition is expected to be completed in the third quarter of this year.

Valeda Light Delivery System

Valeda Light Delivery System is a system that uses Photobiomodulation (PBM) technology.Non-invasive treatmentDevice, itsUsing light of different wavelengths to stimulate retinal cell activity。

The retina is one of the organs with the highest energy demands in the human body, surpassing even the brain, and retinal cells are among the cells most dependent on energy. Mitochondria play a central role in energy metabolism, and mitochondrial dysfunction can have direct and devastating effects on retinal health.PBM at specific wavelengths can directly stimulate mitochondrial energy production.。

Valeda uses three different light-emitting diodes to stimulate cellular function., which can enhance metabolism and activate cell regeneration,Wavelength of 590nmUsed to reduce vascular endothelial growth factor and cell deposition;Wavelength of 660nmIncreased the oxygen binding of cytochrome C oxidase and has anti-inflammatory effects;Wavelength of 850nmCan stimulate metabolic activity, has anti-inflammatory effects, and reduces cell death.

Valeda Mechanism of Action:

This therapyBy using light of a specific wavelength to stimulate retinal cells，Activation of Mitochondrial Respiratory Chain Components, promoting cell proliferation and protection, thereby improving vision.
PBM throughTargeted photoreceptors in tissues absorb photons to function., The secondary cellular effects includeIncreased energy production and altered signaling patterns, such as reactive oxygen species (ROS), nitric oxide (NO), and changes in intracellular calcium, thereby promoting cell proliferation and cell protection.
PBM activates mitochondrial respiratory chain components, especiallyCytochrome C Oxidase (Cox)To play a role. Cox is the terminal enzyme of the mitochondrial electron transport chain and is crucial for ATP production. When exposed to infrared or near-infrared light, Cox can be activated in either oxidized or reduced forms, thereby increasing mitochondrial membrane potential and promoting ATP synthesis.

# Clinical Trial Progress

LIGHTSITE IIIB is a prospective, open-label clinical trial, enrolling participants who have completedLIGHTSITE IIIPatients in the study. The trial design is13 monthsInternal per4 monthsAccept a roundPBM Therapy, each round includes9 treatments, each time about4 minutes/eye。

InLIGHTSITE 3In the trial,ValedaReached the primary endpoint, and has been proven to be safe and effective. Studies show that in24Within months,ValedaCan achieve the best corrected vision(BCVA)Improve Beyond5A letter, equivalent to one line improvement on the vision chart.

LIGHTSITE 3BResults of the Extended TrialThe pivotal trial2Annual Vision Benefits Extended to4.5Years, and demonstrated good safety。

Data Show

UndergoingPBM TherapyAmong the patients, more than 60% completed the two-phase trial.Best Corrected Visual AcuityIncrease from BaselineMore than 5 letters, which is approximately equivalent to improving one line on the vision chart.；
Geographic Atrophy (GA)Proportion of new cases inPBM GroupFor1.1%, Control group is10%, with statistical significance (p=0.025);
The treatment was well tolerated, with no serious adverse events observed, and high patient compliance.

The researchers pointed out that after the initial treatment ended20 monthsDuring the non-intervention period, some visual improvements were still maintained, and after restarting treatment, patientsBCVARising Again`, Prompt`PBM TherapyWith a certain degree of repeatability and continuity。

▲Source of the article: MedTF, Eye Future

▲Please indicate the above source for reprint.

Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please exercise caution. If it involves issues related to the content, copyright, or other aspects of the work, to ensure the rights and interests of both parties, please contact us and we will handle it immediately. If any platform reprints this article, it must take responsibility for the content itself. The Medical Device Innovation Network is not responsible for any secondary dissemination caused by reprints.

PAST/PREVIEW

Major Personnel Changes at GE, The new president will take office on "May Day"!

Giant Battle! Who Can Take Down the BD200 Billion "Big Cake"?

Tears in the Industry, United Imaging Bags Another 113 Million RMB Mega Contract!